Upon obtaining approval from the Food and Drug Administration, the plaintiffs claim the defendants “unilaterally cancelled plaintiffs’ manufacturing and distribution rights, and unfairly demanded that plaintiffs agree to new, less favorable terms, or else defendants would choose a new manufacturer and cut plaintiffs out entirely. When plaintiffs refused to capitulate to defendants’ deceptive scheme, defendants made good on their threats by deserting the deal and ignoring plaintiffs’ demands for just compensation,” according to the complaint.

Click Here To Read The Full Article